title: Glomerular diseases: FSGS.
abstract: FSGS is a lesion, not a disease. The separation into primary FSGS (a result of immunologic-mediated injury) versus secondary FSGS (related to a variety of causes) is often difficult. Even when this particular issue is carefully evaluated, the therapeutic implications are not always apparent. Newer literature on both biomarker discovery and on the genetic basis of FSGS is reviewed in this context. In addition, the thorny implications of obesity as it relates to the FSGS lesion are discussed. An overall practical algorithmic approach to the management and treatment of the FSGS lesion that integrates these controversial overlap areas is suggested.
authors.affiliation: Division of Nephrology, University Health Network, University of Toronto, Toronto, Canada.
authors.forename: Bhadran
authors.initials: B
authors.lastname: Bose
authors.forename: Daniel
authors.initials: D
authors.lastname: Cattran
mesh_terms: D001706:Biopsy; D005819:Genetic Markers; D005923:Glomerulosclerosis, Focal Segmental / Q000175:diagnosis / Q000235:genetics / Q000276:immunology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007678:Kidney Glomerulus / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D011237:Predictive Value of Tests; D016896:Treatment Outcome
chemical_list: D005819:Genetic Markers; D007166:Immunosuppressive Agents